viernes, 18 de noviembre de 2022

Post COVID-19 Symptoms?

Post COVID-19 Symptoms?

 

Nesma Nabil Ahmed Elgohary (1)

Mohamed Nazmy Farris (2)

Diaa Marzouk Abdel Hamid (1,3)

Mohamed Farouk Allam (1,3)

Salwa Mostafa Mohammad Abdel Rahman (1,4)

 

1. Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

2. Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

3. Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

4. Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

 

World Journal of Medical Microbiology, 2022, 1, 478

 

DOI: 10.31586/wjmm.2022.478

 

Abstract:

The SARS-COV-2 rapid spread caused an international public health emergency with unprecedented rates of morbidity and mortality. Post COVID-19 condition occurs as a spectrum of symptoms that present four or more weeks after acute infection with SARS-CoV-2. Most published data to date state 50-70% of hospitalized patients experienced at least one post-acute COVID-19 symptom up to 3 months after discharge. Commonly reported symptoms include; neurocognitive post COVID-19 (fatigue, dizziness, inattention, and brain fog), respiratory post-COVID (dyspnea, chest pain, and cough), and mental health related symptoms (insomnia, depression, and post-traumatic stress disorder). Additionally, gastro-intestinal post COVID-19 (diarrhea, vomiting, and abdominal pain) along with decline in quality of life and decreased ability to perform activities of daily living were reported. The response to post COVID-19 symptoms is still in its infancy despite being an emerging crisis as scientific evidence and robust data are nonetheless required for clear definition, identification of time frame, classification and management of the condition. New studies are needed to identify total and individual incidence/prevalence rates of different clinical presentations of post COVID-19 symptoms. These future studies will help us to o improve early recognition of long term symptoms after acute infection of COVID-19.

 

Keywords: Post COVID-19, COVID-19, Fatigue, Brain Fog, Dyspnea, Insomnia, Depression, Quality of Life.

 

World Journal of Medical Microbiology, 2022, 1, 478

 

https://www.scipublications.com/journal/index.php/wjmm/article/view/478

Ivermectin for Treatment of COVID-19?

 Ivermectin for Treatment of COVID-19?

 

Hemat Abd El Salam Ahmed Salama (1)

Mohamed Abd El-Rahman Hassan El-Shayeb (2)

Ahmed Nour El-Din Hassan (3,4)

Ghada Essam El-Din Amin (1,5)

Mohamed Farouk Allam (1)

Eman El- Sayed Ahmed (2)

 

1. Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

2. Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

3. Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

4. Department of Clinical Pharmacology, Faculty of Medicine, Galala University, Cairo, Egypt.

5. Department of Community Medicine, Faculty of Medicine, 6th of October University, Cairo, Egypt.

 

World Journal of Medical Microbiology, 2022, 1, 474

 

DOI: 10.31586/wjmm.2022.474

 

Abstract:

Many attempts have been made to repurpose existing and approved drugs for the treatment of COVID-19 infection. This involves anti-malarial drugs such as hydroxychloroquine and chloroquine, which have been shown to be less successful than initially believed, with a substantial risk of often fatal complications and interactions. This also involves Remdesivir, which has been shown to decrease recovery time significantly in hospitalized patients. However, for patients who are not yet hospitalized, there is no currently accepted treatment. Treating patients before they need to be admitted or even prophylactically could greatly decrease the load on hospitals, protect healthcare workers and reduce the spread of COVID-19. An in-vitro study indicated that Ivermectin was dynamic against COVID-19-infected cell. Ivermectin has antimicrobial, antiviral, and anticancer, immunomodulatory properties. This drug could reduce the viral load in COVID-9 infected patients, with potential effect on disease progression and spread. Therefore, Ivermectin may be a therapeutic choice for treatment of COVID-19, however, there is still a lack of evidence-based studies to support ivermectin treatment of patients with COVID-19.

 

Keywords: Coronavirus, COVID-19, Ivermectin, Treatment, Review.

 

World Journal of Medical Microbiology, 2022, 1, 474

 

https://www.scipublications.com/journal/index.php/wjmm/article/view/474